BusinessFirst U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA ClearanceBy Nasdaq OMXFeb 6, 2017, 11:00 AM UTC